166 related articles for article (PubMed ID: 37129184)
1. Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report.
Ibrahimi AK; Al-Hussaini M; Laban DA; Ammarin R; Wehbeh L; Al-Mousa A
CNS Oncol; 2023 Jun; 12(2):CNS97. PubMed ID: 37129184
[TBL] [Abstract][Full Text] [Related]
2. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK.
Borner M; Koeberle D; Von Moos R; Saletti P; Rauch D; Hess V; Trojan A; Helbling D; Pestalozzi B; Caspar C; Ruhstaller T; Roth A; Kappeler A; Dietrich D; Lanz D; Mingrone W;
Ann Oncol; 2008 Jul; 19(7):1288-1292. PubMed ID: 18349029
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
4. A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.
Sato Y; Hirakawa M; Ohnuma H; Takahashi M; Okamoto T; Okamoto K; Miyamoto H; Muguruma N; Furuhata T; Takemasa I; Kato J; Takayama T
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1133-1139. PubMed ID: 29038850
[TBL] [Abstract][Full Text] [Related]
5. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
Adams RA; Meade AM; Madi A; Fisher D; Kay E; Kenny S; Kaplan RS; Maughan TS
Br J Cancer; 2009 Jan; 100(2):251-8. PubMed ID: 19165196
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
7. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Maughan TS; Adams RA; Smith CG; Meade AM; Seymour MT; Wilson RH; Idziaszczyk S; Harris R; Fisher D; Kenny SL; Kay E; Mitchell JK; Madi A; Jasani B; James MD; Bridgewater J; Kennedy MJ; Claes B; Lambrechts D; Kaplan R; Cheadle JP;
Lancet; 2011 Jun; 377(9783):2103-14. PubMed ID: 21641636
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ
N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Moosmann N; Heinemann V
Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Sato A; Koizumi W; Mizunuma N; Takiuchi H
Jpn J Clin Oncol; 2010 Oct; 40(10):913-20. PubMed ID: 20462981
[TBL] [Abstract][Full Text] [Related]
12. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Kataoka M; Kanda M; Ishigure K; Matsuoka H; Sato Y; Takahashi T; Tanaka C; Deguchi T; Shibata Y; Sato M; Inagaki H; Matsui T; Kondo A; Takano N; Tanaka H; Sakamoto J; Oba K; Kondo K
Ann Surg Oncol; 2017 Feb; 24(2):546-553. PubMed ID: 27638675
[TBL] [Abstract][Full Text] [Related]
13. Severe interstitial pneumonia caused by cetuximab: a case report and review of the literature.
Zhou LY; Chen MH; Shi JN; Ma XJ; Mao XH; Huang P
Anticancer Drugs; 2021 Nov; 32(10):1123-1126. PubMed ID: 34261916
[TBL] [Abstract][Full Text] [Related]
14. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
[TBL] [Abstract][Full Text] [Related]
15. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.
Kim C; Lee JL; Ryu MH; Chang HM; Kim TW; Lim HY; Kang HJ; Park YS; Ryoo BY; Kang YK
Invest New Drugs; 2011 Apr; 29(2):366-73. PubMed ID: 19997960
[TBL] [Abstract][Full Text] [Related]
16. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer.
Yoshida Y; Hoshino S; Aisu N; Naito M; Tanimura S; Sasaki T; Takeno S; Yamashita Y
Case Rep Oncol; 2014 Jan; 7(1):117-21. PubMed ID: 24707258
[TBL] [Abstract][Full Text] [Related]
18. New oxaliplatin-based combinations in the treatment of colorectal cancer.
Cassidy J; Hochster H
Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study).
Hazama S; Maeda H; Iwamoto S; Kim HM; Takemoto H; Kobayashi K; Sakamoto J; Nagata N; Oba K; Mishima H
Clin Colorectal Cancer; 2016 Dec; 15(4):329-336. PubMed ID: 27507128
[TBL] [Abstract][Full Text] [Related]
20. Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia.
Delahunty R; Lee M; Wong HL; Johns J; Mckendrick J; Lee B; Kosmider S; Cooray P; Ananda S; Desai J; Tran B; Tie J; Gibbs P; Wong R
Intern Med J; 2020 Feb; 50(2):165-172. PubMed ID: 30887616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
